XML 13 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current Assets:    
Cash and cash equivalents $ 141,139 $ 128,994
Marketable securities 229,063 213,591
Accounts receivable, net of reserves of $4,896 in 2016 and $5,128 in 2015 212,229 188,318
Inventories 175,688 188,833
Deferred income tax assets   39,829
Other current assets 62,991 62,069
Total current assets 821,110 821,634
Long-Term Assets:    
Property and equipment, net 347,161 333,026
Goodwill 180,657 178,934
Intangible assets, net 49,729 55,909
Other long-term assets 90,584 85,490
Total long-term assets 668,131 653,359
TOTAL ASSETS 1,489,241 1,474,993
Current Liabilities:    
Accounts payable 50,085 52,648
Accrued liabilities 188,842 205,530
Line of credit 558,000 573,000
Current portion of deferred revenue 25,849 25,583
Total current liabilities 822,776 856,761
Long-Term Liabilities:    
Deferred income tax liabilities 16,419 49,389
Long-term debt 597,958 597,085
Long-term deferred revenue, net of current portion 30,258 27,055
Other long-term liabilities 30,328 28,698
Total long-term liabilities 674,963 702,227
Total liabilities 1,497,739 1,558,988
Commitments and Contingencies (Note 13)
Stockholders’ Deficit:    
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 102,831 and 102,237 shares in 2016 and 2015, respectively 10,283 10,258
Additional paid-in capital 972,360 940,534
Deferred stock units: Outstanding: 231 and 240 units in 2016 and 2015, respectively 5,482 5,409
Retained earnings 431,577 318,356
Accumulated other comprehensive loss (35,465) (42,265)
Treasury stock, at cost: 13,271 and 12,242 shares in 2016 and 2015, respectively (1,392,875) (1,316,417)
Total IDEXX Laboratories, Inc. stockholders’ deficit (8,638) (84,125)
Noncontrolling interest 140 130
Total stockholders’ deficit (8,498) (83,995)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 1,489,241 $ 1,474,993